India shouldn't neglect U.S. pharma's call for greater IP protection

06/26/2013 | Reuters

India has good reasons to listen to U.S. drugmakers' arguments for stronger patent protection, Katrina Hamlin writes. Compromising intellectual property is not the solution to India's undeniably critical health needs, because domestic drugmakers will in the long run benefit from improved patent protection, she writes.

View Full Article in:


Published in Brief: